Why Cardiothoracic Surgery Still Matters: Sustaining a Critical Specialty and Building Its Future

The Narrative We Need to Correct

Every few years, the same headline resurfaces. Cardiothoracic surgery is a dying specialty. Interventional cardiology has taken over the operating room. The robots will do the rest. It is a clean story, easy to tell, and almost entirely wrong.

The premise rests on a selective reading of procedure-mix data and a fundamental misunderstanding of what a cardiothoracic surgeon actually does inside a hospital. Isolated CABG volumes peaked in the early 2000s and have since declined. That part is true. What the narrative conveniently ignores is everything else: the explosion of structural heart disease driven by an aging population, the expanding indications for mechanical circulatory support, the U.S. Preventive Services Task Force (USPSTF)-driven growth in lung cancer screening and its downstream surgical demand, and the simple demographic reality that 10,000 Americans turn 65 every single day. The question is not whether there will be enough work for us. The question is whether there will be enough of us for the work.

The Data Tell a Different Story

In 2009, the workforce projections were dire. A widely cited Circulation analysis predicted a deficit of 2,000 cardiothoracic surgeons by 2030. Entire conferences were organized around the premise of managed decline. Here is what actually happened: between 2005 and 2021, the number of practicing cardiothoracic surgeons in the United States grew from roughly 4,000 to 5,200. The number of trainees more than doubled, from 230 in 2008 to 519 in 2023. The 2025 thoracic surgery match achieved a 100 percent fill rate for the first time, with the integrated I-6 pathway expanding from three positions in 2007 to 48 positions in 2025 and applications increasing by 150 percent. The specialty that was supposed to disappear is attracting more candidates than it has seats.

A 2025 analysis published in the Heart Surgery Forum confirmed what practicing surgeons already sense on the ground: the workforce gap is narrowing, not widening. Residency programs are graduating an average of 127 new surgeons annually, a 13 percent increase from a decade ago. The gap has not vanished entirely, and it will not. Health Resources and Services Administration projects a 31 percent shortfall by 2035 relative to demand, with 900 surgeons expected to retire while total procedural demand increases by 20 percent. But a supply-demand gap is not a dying specialty. It is the opposite. It is a field in which demand is outpacing our ability to produce trained surgeons fast enough.

The Demand Drivers Nobody Wants to Talk About

Consider the aortic stenosis pipeline alone. Between 2012 and 2019, the overall rate of aortic valve replacement among Medicare beneficiaries increased by nearly 60 percent. TAVR did not replace SAVR and then stop. TAVR unlocked an entirely new patient population: the octogenarian who was previously told to go home and manage symptoms medically because open surgery was too risky. The total number of patients receiving valve interventions is larger than at any point in history, and it continues to grow. TAVR volumes are projected to increase fourfold over the next decade. Someone has to manage the failures, the endocarditis on bioprosthetic valves, the paravalvular leaks that cannot be closed percutaneously, and the structural valve degeneration that is already arriving in patients who received their first TAVR five to seven years ago. That someone is a cardiothoracic surgeon.

Then there is mechanical circulatory support. ECMO utilization has surged: Vanderbilt reported a 75 percent increase in ECMO patients in a single fiscal year. Impella, TandemHeart, and durable left ventricular assist devices are not cardiologist-only technologies. They require a surgical team that can implant, troubleshoot, and explant. The growth of heart failure programs, transplant programs, and advanced lung disease programs is tethered directly to the availability of cardiothoracic surgeons. Without us, these programs do not exist.

On the thoracic side, the 2021 USPSTF expansion of lung cancer screening eligibility to adults aged 50 and older with a 20-pack-year smoking history doubled the number of Black Americans and women eligible for screening and expanded the screening-eligible population to approximately 14.6 million Americans. Earlier detection means more early-stage lung cancers, and early-stage lung cancers are surgical diseases. The demand for anatomic lung resection, whether open, video-assisted, or robotic, is set to rise in lockstep with screening penetration, which itself remains below optimal levels and has significant room to grow.

The Institutional Backbone: What a Cardiothoracic Surgery Program Really Means to a Hospital

Here is where the standard conversation goes wrong. When hospital administrators evaluate cardiothoracic surgery, they tend to look at contribution margins per case, operating room utilization rates, and direct procedural revenue. Those metrics matter, but they are measuring the shadow on the wall and calling it the fire.

A cardiothoracic surgery program is not just another service line. It is the structural prerequisite for an entire ecosystem of high-acuity clinical services. Consider what happens when a hospital loses its cardiothoracic surgery capability. Level I trauma center designation requires 24-hour availability of a cardiothoracic surgeon and cardiopulmonary bypass capability. No CT surgery program, no Level I designation. That single loss cascades: trauma volumes drop, the emergency department contracts, orthopedic trauma referrals disappear, neurosurgery loses its safety net for thoracic spine injuries with major vascular involvement, and the hospital's competitive position in its market erodes in ways that no amount of outpatient clinic expansion can offset.

Cardiology cannot function at the highest level without a surgical partner. Structural heart programs depend on a cardiac surgeon in the room for TAVR, in the building for bailout, and on the staff for the cases that cannot be done percutaneously. Electrophysiology programs that offer surgical ablation or lead extraction require a surgeon who can deal with a major vascular injury. Heart failure programs that want to offer implantation of left ventricular assist devices and transplantation need a surgeon who can do both. Pulmonology programs that want to offer advanced bronchoscopy, navigational platforms, and interventional procedures benefit enormously from the presence of a thoracic surgeon who can manage the complications, biopsy the nodules that cannot be reached endobronchially, and operate on the cancers those programs find. Interventional gastroenterology programs that perform complex esophageal procedures rely on thoracic surgical backup for perforation management and definitive oncologic resection.

The cardiothoracic surgeon is the clinical anchor that allows other specialties to practice at the top of their scope. Take away the anchor, and the entire fleet drifts.

Beyond the Spreadsheet: The Value We Cannot Invoice

Hospital administrators tend to value a cardiothoracic surgeon through three narrow lenses: relative value units, contribution margin per case, weeks of call covered, and formal backup on procedures such as lead extractions and high-risk percutaneous interventions. Compensation models built only on those metrics chronically underprice the role, because the value we generate is largely structural and downstream, invisible on a per-case spreadsheet and obvious the moment the program is gone.

There is a dimension of what cardiothoracic surgeons bring to a hospital that never appears on a balance sheet. We are the physicians who are called when the problem is unsolvable, when the airway is lost, when the chest needs to be opened in the emergency department, when the bleeding cannot be controlled by anyone else in the building. That capability, the knowledge that someone is available who can perform a thoracotomy or sternotomy expeditiously and cross-clamp an aorta, shapes the confidence of every other service in the hospital. Trauma surgeons operate differently when they know a cardiac surgeon is available. Interventional cardiologists are willing to take on more complex percutaneous coronary intervention when they know a surgical team is one phone call away, and that backstop is part of why the most challenging cases get offered at all. Pulmonologists biopsy lesions adjacent to the hilum when they know a thoracic surgeon can manage the consequences.

This is not soft value. It is the infrastructure of institutional courage. Hospitals with strong cardiothoracic surgery programs take on sicker patients, offer more complex services, attract better trainees, and ultimately build the kind of reputation that sustains referral networks for decades. The economics follow that pattern. Programs that perform cardiac surgery routinely carry higher case-mix indices than peer hospitals without surgical capability, because cardiac procedures sit among the heaviest weighted diagnosis-related groups in inpatient medicine. The presence of a cardiothoracic program also reshapes payer mix, drawing an older, predominantly Medicare-insured population whose downstream admissions extend across cardiology, pulmonary, vascular, and critical care lines. Hospitals that eliminate or downsize their cardiothoracic programs to chase short-term margin improvement often discover, too late, that they have pulled the keystone from an arch that had been silently bearing the weight of every adjacent service line.

There is also the matter of institutional quality measurement. The STS Adult Cardiac Surgery Database (ACSD) is one of the most sophisticated quality benchmarking systems in all of medicine. Participation in the ACSD, with voluntary individual surgeon scorecard reporting, feeds directly into CMS star ratings, U.S. News hospital rankings, and state-level reporting programs. A hospital with a high-performing cardiothoracic surgery program does not just perform heart operations. It demonstrates, with public data, that it is a place where clinical excellence is measured, reported, and improved. That signal travels far beyond the cardiac OR.

Bringing Them In: How We Make the Next Generation Want This

If the workforce data and the institutional value proposition are this strong, why does the perception problem persist? And more importantly, how do we make medical students want to be us?

The obstacles are well documented. Length of training. Perceived lifestyle sacrifice. Gender disparity in the pipeline: roughly half of medical students are women, but more than 90 percent of cardiothoracic trainees are men. The intimidation factor of the cardiac operating room, which can feel like walking onto the bridge of an aircraft carrier for a third-year student who has never witnessed a sternotomy. And, perhaps most corrosive of all, the casual nihilism from other specialties. How many medical students have been told by an attending in another field not to bother with cardiac surgery because it is all going to be done with catheters in ten years? That line has been repeated since the 1990s, and yet here we are, operating.

The solutions are not mysterious; they are operational. First, we need earlier and more intentional exposure. Accreditation Council for Graduate Medical Education minimum case requirements for general surgery do not guarantee meaningful cardiothoracic exposure, and most medical students never see a sternotomy until late in their training, if at all. Cardiothoracic surgery interest groups, simulation labs, and structured mentorship programs that begin in the first and second year of medical school, not the fourth, when career decisions have already been made. Second, we need to demystify the operating room. Published work in Annals of Thoracic Surgery Short Reports has shown that the skills and expectations of the cardiothoracic operating room are not evident to students. Explicit guides on etiquette, behavioral norms, and the specific ways a medical student can be useful in a cardiac case would remove a significant barrier. Third, we need to be visible. Medical students choose specialties based on the people they encounter. If the only cardiothoracic surgeon they see is a burned-out attending who arrives at 5 a.m. and leaves at 9 p.m., the message is clear. If instead they see a surgeon who is intellectually engaged, academically productive, technically excellent, and present enough to actually teach, the message is entirely different.

Fourth, the demographics of our pipeline have to change. We need to actively recruit women and underrepresented minorities into cardiothoracic training. A specialty that looks like only one segment of the population will always struggle to attract the other segments. The integrated I-6 pathway has created an opportunity to reach students earlier, before the culture of general surgery residency filters out candidates who might have thrived in cardiothoracic training. We should be leveraging that pathway aggressively, pairing it with funded research opportunities, mentorship networks, and financial support that removes economic barriers to a long training period.

Finally, we need to stop apologizing for the difficulty of the work. The length of training, the intensity of the cases, the weight of the decisions: these are not defects of the specialty. They are the reasons the specialty matters. We hold hearts in our hands and repair them. We rebuild aortas. We remove cancers from lungs and give people years they would not otherwise have. There is no other field in medicine where the stakes are this immediate, the feedback this direct, and the opportunity to change a life this concrete. That story, told well and told often, is the most powerful recruitment tool we have.

A Charge to Early-Career Surgeons

We are the generation that will determine whether cardiothoracic surgery thrives or merely survives. The demographic forces are in our favor. The procedural demand is there. The institutional need is undeniable. What remains to be seen is whether we will advocate for our specialty with the same intensity we bring to the operating room. That means publishing. It means mentoring. It means showing up at the medical school and not just the OR. It means making the case to hospital administrators who may not understand what they have until it is gone. It also entails telling the truth about what we do, without exaggeration but without apology, to anyone who will listen.

Cardiothoracic surgery is not in decline. It is evolving, it is expanding, and it is more essential to the American hospital than it has ever been. The only real risk is that we fail to make the case ourselves, and cede the framing of our specialty to administrators and commentators who neither perform the work nor understand its institutional weight.